In patients with CAPS, NLRP3 mutations trigger constitutive production of IL-1β, resulting in fever, neutrophilic urticaria, conjunctivitis, arthralgia, and elevated acute-phase reactants, which can be alleviated via IL-1-blocking treatment (de Jesus et al., 2015). The gene discussed is NLRP3; the disease is cryopyrin-associated periodic syndrome.